Aspergillosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Aspergillosis

Aspergillosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Aspergillosis is a fungal infection caused by Aspergillus, a species of mold that is found all over the world. Aspergillosis is a fungal infection caused by certain types of mold. Only about 40  species of Aspergillus are known to associated with disease in humans.

Aspergillosis has several different forms including:

Allergic bronchopulmonary aspergillosis (ABPA)- usually occurs in individuals with long-standing asthma or cystic fibrosis.

Allergic Aspergillus sinusitis- cause a stuffy nose, runny nose, congestion, fever, facial pain and headache.

Invasive aspergillosis- occur in individuals who have a weakened immune system including people who have low levels of neutrophils (neutropenia).

Chronic pulmonary aspergillosis- characterized by scarring (fibrosis) within the lungs and the gradual loss of lung tissue which causes the formation of empty spaces (cavitation), or the widening and growth  (expansion) of existing spaces and thickening of the membranes around the lungs (pleural thickening).

Cutaneous (skin) aspergillosis

Epidemiology- According to Thelansis, about 2.5% of adults who have asthma also have ABPA, which is approximately 4.8 million people worldwide. Of these 4.8 million people who have ABPA, an estimated 400,000 also have chronic pulmonary aspergillosis (CPA). Another 1.2 million people are estimated to have CPA after having tuberculosis, and over 70,000 people are estimated to have CPA as a complication of sarcoidosis. The number of hospitalizations related to invasive aspergillosis in the United States increased an average of 3% per year during 2000- 2013.

KOLs insights of Aspergillosis across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Competitive landscape of Aspergillosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Aspergillosis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Aspergillosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        dupilumab        Regeneron Pharmaceuticals        Phase 3

2        isavuconazole        Astellas Pharma Inc        Phase 3

3        Posaconazole        Merck Sharp & Dohme Corp.        Phase 2

4        SCY-078        Scynexis, Inc.        Phase 2

5        F901318        F2G Biotech GmbH        Phase 1

6        PC945        Pulmocide Ltd        Phase 1

7        Voriconazole        Chong Kun Dang Pharmaceutical        Phase 1
 

Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Gastroparesis

Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from stomach to small intestine. Gastroparesis is caused when vagus nerve is damaged or stops working. The vagus nerve gets damaged if someone has diabetes and blood sugar or blood glucose levels stay high over a long period of time.

The vagus nerve controls how food moves through digestive tract. When this nerve doesn’t work well, food moves too slowly or stops moving.

Other causes of gastroparesis include: anorexia or bulimia, chronic fatigue syndrome, amyloidosis, scleroderma, Parkinson's disease, abdominal migraine, hypothyroidism

Gastroparesis can be classified into three types:

Diabetic gastroparesis

Idiopathic gastroparesis

Post-surgical gastroparesis

Epidemiology- According to Thelansis, Gastroparesis affects approximately 4% of the population and is more common in women. Many people with gastroparesis also have diabetes, and 50% of those affected had diabetes before the onset of their gastroparesis.

Competitive landscape of Gastroparesis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Gastroparesis across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Gastroparesis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        Velusetrag        Theravance Biopharma        Phase 2

2        CNSA-001        PTC Therapeutics        Phase 2

3        CIN-102        CinDome Pharma, Inc.        Phase 2

4        Tradipitant        Vanda Pharmaceuticals        Phase 3

5        Camicinal        GlaxoSmithKline        Phase 2

6        Nimacimab        Bird Rock Bio, Inc.        Phase 2

7        Metoclopramide Nasal Spray        Evoke Pharma        Phase 3

8        Neurogastrx, Inc.        Neurogastrx, Inc.        Phase 2

9        IW-9179        Ironwood Pharmaceuticals, Inc.        Phase 2

10        TAK-906 Maleate        Takeda        Phase 2

11        Itopride        Forest Laboratories        Phase 2

12        RM-131        Motus Therapeutics, Inc.        Phase 2

13        Relamorelin        Allergan        Phase 2"

Spinal cord injury (SCI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Spinal cord injury (SCI)

Spinal cord injury (SCI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

A spinal cord injury (SCI) is damage to the spinal cord that results in a loss of function, such as mobility and/or feeling. Spinal cord injuries are most often the result of vehicle accidents, which account for 39.3% of SCI cases, followed closely by falls (31.8%). Other causes include acts of violence (primarily gunshot wounds) at 13.5% and sports-related injuries at 8%.

Spinal cord injury can be classified into four categories: cervical, thoracic, lumbar and sacral.

Cervical spinal cord injuries usually cause loss of function in the arms and legs, resulting in quadriplegia

The 12 vertebra in the chest are called the thoracic vertebra.

The vertebra in the lower back between the thoracic vertebra, where the ribs attach, and the pelvis (hip bone), are the lumbar vertebra.

The sacral vertebra run from the pelvis to the end of the spinal column.

SCIs are graded according to the American Spinal Injury Association (ASIA) grading scale, which describes the severity of the injury. The scale is graded with letters:

ASIA A: injury is complete spinal cord injury with no sensory or motor function preserved.

ASIA B: a sensory incomplete injury with complete motor function loss.

ASIA C: a motor incomplete injury, where there is some movement, but less than half the muscle groups are anti-gravity (can lift up against the force of gravity with a full range of motion).

ASIA D: a motor incomplete injury with more than half of the muscle groups are anti-gravity.

ASIA E: normal.

Epidemiology- According to Thelansis, an estimated 311,000 people in the United States are living with spinal cord injuries (SCIs). There are approximately 19,350 new SCIs every year, most of which are caused by automobile accidents and falls. About ~80% of new SCI cases are male.

 

Competitive landscape of Spinal cord injury (SCI) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Spinal cord injury (SCI) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. KOL Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Spinal cord injury (SCI) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Spinal cord injury (SCI) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        FAB117-HC        Ferrer Internacional S.A.        Phase 2

2        AXER-204        ReNetX Bio, Inc.        Phase 2

3        KP-100IT        Kringle Pharma, Inc.        Phase 3

4        SC0806 and rehabilitation        BioArctic AB        Phase 2

5        Cethrin        Vertex Pharmaceuticals Incorporated        Phase 2

6        Neuro-Cells        Neuroplast        Phase 1

7        ES135        Eusol Biotech Co., Ltd.        Phase 3

8        GRNOPC1        Lineage Cell Therapeutics, Inc.        Phase 1

9        MT-3921        Mitsubishi Tanabe Pharma Development America, Inc.        Phase 2

10        Elezanumab        AbbVie        Phase 2

 

Retinitis pigmentosa (RP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Retinitis pigmentosa (RP)

Retinitis pigmentosa (RP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Retinitis pigmentosa (RP) comprises a large group of inherited vision disorders that cause progressive degeneration of the retina, the light sensitive membrane that coats the inside of the eyes. Retinitis pigmentosa is a group of hereditary progressive disorders that may be inherited as autosomal recessive, autosomal dominant or X-linked recessive traits. The RP11 gene (PRPF31) causing autosomal dominant RP.

Epidemiology- According to Thelansis, It is generally estimated that the disorder affects roughly 1 in 4,000 people, both in the United States and worldwide.

Competitive landscape of Retinitis pigmentosa (RP) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Retinitis pigmentosa (RP) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Retinitis pigmentosa (RP) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Retinitis pigmentosa (RP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        AAV2/5-RPGR        MeiraGTx UK II Ltd        Phase 2

2        CPK850        Novartis Pharmaceuticals        Phase 2

3        BS01        Bionic Sight LLC        Phase 2

4        AAV2/5-hPDE6B        Horama S.A.        Phase 2

5        RST-001        Allergan        Phase 2

6        hRPC        ReNeuron Limited        Phase 2

7        4D-125 IVT Injection        4D Molecular Therapeutics        Phase 2

8        rAAV2tYF-GRK1-RPGR        Applied Genetic Technologies Corp        Phase 2

9        NT-501        Neurotech Pharmaceuticals        Phase 2

10        Minocycline        The Emmes Company, LLC        Phase 2

11        vMCO-I        Nanoscope Therapeutics Inc.        Phase 2

12        rhNGF 180 µg/ml        Dompé Farmaceutici S.p.A        Phase 2

13        QR-1123        ProQR Therapeutics        Phase 2

14        NPI-001        Nacuity Pharmaceuticals, Inc.        Phase 2"
 

Ewing Sarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Ewing Sarcoma

Ewing Sarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Ewing sarcoma has also been called peripheral primitive neuroectodermal tumor is a type of tumor that forms from a certain kind of cell in bone or soft tissue. In Ewing sarcoma, the chromosomal areas involved are the long arms (q) of chromosome 11 and 22 (11q24-22q12). These pieces break off and trade places. In most cases, this results in the abnormal fusion of two genes, usually the EWS and FLI genes.

Ewing sarcoma is described as localized, metastatic, or recurrent.

Localized Ewing sarcoma- The cancer is found in the bone or soft tissue where it began and may have spread to nearby tissue, including nearby lymph nodes.

Metastatic Ewing sarcoma- The cancer has spread from the bone or soft tissue where it began to other parts of the body. In Ewing tumor of bone, the cancer most often spreads to the lung, other bones, and bone marrow.

Recurrent Ewing sarcoma- The cancer has recurred (come back) after it has been treated. The cancer may come back in the bone or soft tissue where it began or in another part of the body.

Epidemiology- According to Thelansis, the annual incidence of Ewing sarcoma is 2.93 children per 1,000,000. Approximately 200-250 children and adolescents in the United States are diagnosed with a tumor in the Ewing family of tumors each year. Two-thirds will be long-term survivors (more than five years).

Competitive landscape of Ewing Sarcoma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Ewing Sarcoma across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Ewing Sarcoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Ewing Sarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No     Asset     Company            Stage
1 CLR 131 Cellectar Biosciences, Inc. Phase 1
2 pemetrexed Eli Lilly and Company Phase 2
3 racotumomab Laboratorio Elea Phoenix S.A. Phase 1
4 Temozolomide Gradalis, Inc. Phase 2
5 SP-2577 Salarius Pharmaceuticals, LLC Phase 1
6 TK216 Oncternal Therapeutics, Inc Phase 1
7 Imatinib mesylate Novartis Pharmaceuticals Phase 2
8 Enoblituzumab MacroGenics Phase 1
9 Lipegfilgrastim Teva Pharmaceutical Industries Phase 1
10 TB-403 Oncurious NV Phase 1
Continued...
 

Myelofibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Myelofibrosis

Myelofibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Myeloproliferative neoplasms is a rare disorder in which abnormal blood cells and fibers build up in the bone marrow. The genes most frequently associated with MF are Janus kinase 2 gene (JAK2) and calreticulin gene (CALR).

Epidemiology- According to Thelansis, it is estimated that the annual incidence in the United States population is 1.5 cases per 100,000 persons in the United States.

Competitive landscape of Myelofibrosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Myelofibrosis across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Myelofibrosis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Myelofibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        PXS-5505        Pharmaxis        Phase 2

2        KRT-232        Kartos Therapeutics, Inc.        Phase 2

3        Ruxolitinib        Incyte Corporation        Phase 1

4        Selinexor        Karyopharm Therapeutics Inc        Phase 2

5        Ruxolitinib        Novartis Pharmaceuticals        Phase 2

6        SAR302503 (TG101348)        Sanofi        Phase 2

7        APG-1252        Ascentage Pharma Group Inc.        Phase 2

8        Pacritinib        PSI CRO        Phase 3

9        FEDRATINIB        Celgene        Phase 3

10        NS-018        Nippon Shinyaku Co., Ltd.        Phase 2

11        NS-018        NS Pharma, Inc.        Phase 2

12        GB2064        Galecto Biotech AB        Phase 2

13        BMS-986158        Bristol-Myers Squibb        Phase 1

14        Ruxolitinib        Actuate Therapeutics Inc.        Phase 2

15        Imetelstat        Geron Corporation        Phase 3

16        TL-895        Telios Pharma, Inc.        Phase 2

17        Jaktinib Hydrochloride Tablets        Suzhou Zelgen Biopharmaceuticals Co.,Ltd        Phase 2

18        Navitoclax        AbbVie        Phase 3

19        APLIDIN (plitidepsin)        PharmaMar        Phase 2

20        rabbit anti-thymocyte globulin (ATG)        Otsuka America Pharmaceutical        Phase 2

21        Simtuzumab        Gilead Sciences        Phase 2

22        TP-3654        Sumitomo Dainippon Pharma Oncology, Inc        Phase 1

23        TBX-2400        Taiga Biotechnologies, Inc.        Phase 1

24        Pevonedistat        Takeda        Phase 1

25        Fostamatinib        Rigel Pharmaceuticals        Phase 2

26        MMB        Sierra Oncology, Inc.        Phase 2

27        IMG-7289        Imago BioSciences,Inc.        Phase 2

28        PU-H71        Samus Therapeutics, Inc.        Phase 1

29        Luitpold Azacitidine        American Regent, Inc.        Phase 1

30        Pacritinib        CTI BioPharma        Phase 2

31        CPI-0610        Constellation Pharmaceuticals        Phase 3

32        AZD1480        AstraZeneca        Phase 1

33        LNK01002        Lynk Pharmaceuticals Co., Ltd        Phase 1

34        CWP232291        JW Pharmaceutical        Phase 1

35        LY2784544        Eli Lilly and Company        Phase 1

36        SP-420        Abfero Pharmaceuticals, Inc        Phase 1

37        MDG1021 dose 1        Medigene AG        Phase 1

38        PRT543        Prelude Therapeutics        Phase 1

39        givinostat        Italfarmaco        Phase 2

40        rigosertib        Onconova Therapeutics, Inc.        Phase 2

41        AC220        Daiichi Sankyo, Inc.        Phase 1

42        Anagrelide CR        Galena Biopharma, Inc.        Phase 2

43        Lorvotuzumab Mertansine (IMGN901)        ImmunoGen, Inc.        Phase 2

44        TAS1553        Astex Pharmaceuticals, Inc.        Phase 1

45        Triciribine        Prescient Therapeutics, Ltd.        Phase 1

46        Ad26.Mos.HIV        Janssen Vaccines & Prevention B.V.        Phase 2"

Idiopathic pulmonary fibrosis (IPF) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Idiopathic pulmonary fibrosis (IPF)

"Idiopathic pulmonary fibrosis (IPF) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Idiopathic pulmonary fibrosis (IPF) is a serious chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs. This condition occurs when that lung tissue becomes thick and stiff for unknown reasons. Over time, these changes can cause permanent scarring in the lungs, called fibrosis, which makes it progressively more difficult to breathe. Usually the breathlessness of IPF first appears during exercise. Breathlessness can affect day-to-day activities such as showering, climbing stairs, getting dressed and eating. As scarring in the lungs gets worse, breathlessness may prevent all activities. About 85% of people with IPF have a chronic cough that has lasts longer than 8 weeks. This is often a dry cough, but some people may also cough up sputum or phlegm.

The exact, underlying cause of IPF is not fully understood. Different factors, including immunologic, environmental, and genetic ones, are thought to play a role in the development of the disorder.  The strongest risk factor, accounting for 30% of risk of developing IPF, is a variation in the MUC5B gene that results in more mucus production in the smallest airways in the lung (respiratory bronchioles). Certain affected individuals are genetically predisposed (susceptible) to developing IPF following such exposures described above. A person who is genetically predisposed to a disorder carries a gene (or genes) for the disease, but it may not be expressed unless it is triggered or “activated” under certain circumstances, such as due to particular environmental or immunologic factors. A number of genes have implicated in the development of IPF and aggregate account for 35-40% of the risk of developing IPF. These genes include genes that preserve host defense, cell survival, and cell-cell interactions.

KOLs insights of Idiopathic pulmonary fibrosis (IPF) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

The epidemiological data, presented by the National Institute of Health (NIH), estimated that IPF has a prevalence of 13 to 20 per 100,000 people worldwide. Moreover, about 100,000 individuals are affected in the United States and nearly 30,000 to 40,000 new cases are diagnosed every year. Also, the overall prevalence of IPF in men and women was 20.2 per 100,000 and 13.2 per 100,000 respectively. The indication usually affects people between the ages of 50 and 70.

Competitive landscape of Idiopathic pulmonary fibrosis (IPF) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Idiopathic pulmonary fibrosis (IPF) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Idiopathic pulmonary fibrosis (IPF) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        GB0139        Galecto Biotech AB        Phase 2

2        tralokinumab cohort        AstraZeneca        Phase 2

3        Nalbuphine ER        Trevi Therapeutics        Phase 2

4        SAR156597        Sanofi        Phase 2

5        Pamrevlumab        FibroGen        Phase 3

6        TRK-250        Toray Industries, Inc        Phase 1

7        VAY736        Novartis Pharmaceuticals        Phase 2

8        PRM-151        Hoffmann-La Roche        Phase 3

9        GLPG1690 600 mg QD        Galapagos NV        Phase 2

10        ART-123        Asahi Kasei Pharma Corporation        Phase 3

11        ORIN1001        Orinove, Inc.        Phase 1

12        Jaktinib Dihydrochloride Monohydrate        Suzhou Zelgen Biopharmaceuticals Co.,Ltd        Phase 2

13        Ifenprodil        Algernon Pharmaceuticals        Phase 2

14        PLN-74809        Pliant Therapeutics, Inc.        Phase 2

15        GSK2126458        GlaxoSmithKline        Phase 1

16        BBT-877        Bridge Biotherapeutics, Inc.        Phase 1

17        HEC585        Sunshine Lake Pharma Co., Ltd.        Phase 1

18        KD025        Kadmon Corporation, LLC        Phase 2

19        BI 1015550        Boehringer Ingelheim        Phase 2

20        Gefapixant        Afferent Pharmaceuticals, Inc.        Phase 2

21        BMS-986020        Bristol-Myers Squibb        Phase 2

22        PBI4050        Liminal BioSciences Ltd.        Phase 2

23        C21        Vicore Pharma AB        Phase 2

24        BG00011        Biogen        Phase 2

25        tipelukast        MediciNova        Phase 2

26        Tyvaso® (treprostinil)        United Therapeutics        Phase 3

27        TD-1058        Theravance Biopharma        Phase 1

28        ND-L02-s0201        Nitto Denko Corporation        Phase 2

29        Lung stem cells        Regend Therapeutics        Phase 2

30        fostair        Chiesi Farmaceutici S.p.A.        Phase 2

31        DWN12088        Daewoong Pharmaceutical Co. LTD.        Phase 1

32        GBT440        Global Blood Therapeutics        Phase 2

33        MG-S-2525        Metagone Biotech Inc.        Phase 1

34        Inhaled Nitric Oxide        Geno LLC        Phase 2

35        CC-90001        Celgene        Phase 2

36        ZSP1603        Guangdong Zhongsheng Pharmaceutical Co., Ltd.        Phase 1

37        inhaled Nitric Oxide        Bellerophon        Phase 1

38        ZL-2102        Zai Lab Pty. Ltd.        Phase 1"

Amyotrophic lateral sclerosis (ALS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Amyotrophic lateral sclerosis (ALS)

"Amyotrophic lateral sclerosis (ALS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that involves the progressive degeneration of the motor neurons of the cerebral cortex, brain stem, and spinal cord. The etiology of ALS is unknown in most cases, but in a subset of patients, the disease is known to be monogenic and/or familial. ALS affects upper motor neurons (UMNs), which originate from the brain, and lower motor neurons (LMNs), which originate from the spinal cord. Signs of UMN dysfunction include spasticity, weakness, slowness of movement, and brisk deep tendon reflexes, while LMN dysfunction signs include muscle fasciculation (spontaneous contraction affecting a small number of muscle fibers), wasting, and weakness.

Mutations in several genes can cause familial ALS and contribute to the development of sporadic ALS. Mutations in the C9orf72 gene account for 30 to 40 percent of familial ALS in the United States and Europe. Worldwide, SOD1 gene mutations cause 15 to 20 percent of familial ALS, and TARDBP and FUS gene mutations each account for about 5 percent of cases. There is an overlap between fALS and sALS in terms of the underlying genetic mutations. Some of the mutations implicated in fALS, such as those of SOD1, TDP-43, and C9orf72, are also implicated in sALS cases, suggesting that investigation of the pathways and targets affected by these mutations may have broader application across the whole ALS spectrum.

Classification of Amyotrophic lateral sclerosis (ALS)

Benign Focal Amyotrophy of ALS

Infantile Spinal Muscular Atrophy, ALS

Juvenile Spinal Muscular Atrophy, Included

Kugelberg-Welander Disease5.

Primary Lateral Sclerosis

Progressive Bulbar Palsy, Included

Spinal Muscular Atrophy, Type ALS

Upper Motor Neuron Disease

Werdnig-Hoffman Disease

Wohlfart-Disease

According to Thelansis, about 5,000 people in the United States are diagnosed with ALS each year. Worldwide, this disorder occurs in 2 to 5 per 100,000 individuals. Only a small percentage of cases have a known genetic cause. The average age of all diagnosed prevalent cases of ALS in the countries under study is 60 and more. Among EU countries, the diagnosed prevalence of ALS is highest in Germany ranges between 7.85 to 8.95 per 100,000.

Competitive landscape of Amyotrophic lateral sclerosis (ALS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Amyotrophic lateral sclerosis (ALS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Amyotrophic lateral sclerosis (ALS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Amyotrophic lateral sclerosis (ALS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        Reldesemtiv        Cytokinetics        Phase 2

2        Albutein 5%        Grifols Therapeutics LLC        Phase 2

3        BIIB067        Biogen        Phase 3

4        Trametinib        GENUV Inc.        Phase 2

5        AMX0035        Amylyx Pharmaceuticals Inc.        Phase 3

6        VM202        Helixmith Co., Ltd.        Phase 2

7        Q-Cells        Q Therapeutics, Inc.        Phase 2

8        E0302 (mecobalamin)        Eisai Co., Ltd.        Phase 3

9        AstroRx        Kadimastem        Phase 2

10        AP-101        AL-S Pharma        Phase 1"

Ependymoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Ependymoma

"Ependymoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Ependymoma is a rare type of tumor of the brain or spinal cord. It can happen in both children and adults. In children, these tumors tend to be in the brain. In adults, they're often in the spinal cord. Literature suggest that people with a genetic disorder called neurofibromatosis type 2 (NF2) have a higher risk of developing an ependymoma.

The World Health Organization (WHO) classifies ependymoma into 3 grades:

Grade I (1): Subependymoma

Grade II (2): Ependymoma or myxopapillary ependymoma

Grade III (3): Anaplastic ependymoma

Grade I is the slowest growing ependymoma, Grade III is fast growing.

According to Thelansis, These tumors have an incident rate of 0.43 patients per 100 000 population in the United States, accounting for 1.8% of all primary brain tumors.

Competitive landscape of Ependymoma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Ependymoma across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Ependymoma Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Ependymoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

S. No        Asset        Company        Stage

1        WP1066        Moleculin Biotech, Inc.        Phase 1

2        valacyclovir        Candel Therapeutics, Inc.        Phase 1

3        Optune NovoTTF-200A System        Hackensack Meridian Health        Phase 1

4        Nivolumab        Bristol-Myers Squibb        Phase 2

5        Gemcitabine        Novartis Pharmaceuticals        Phase 1

6        Selumetinib        AstraZeneca        Phase 2

7        ONC206        Oncoceutics, Inc.        Phase 1

8        Brigatinib        Takeda        Phase 2

9        Indoximod        NewLink Genetics Corporation        Phase 1

10        AXL1717        Axelar AB        Phase 2

11        Polio/Rhinovirus Recombinant (PVSRIPO)        Istari Oncology, Inc.        Phase 1

12        Abemaciclib        Eli Lilly and Company        Phase 1

13        Alisertib        Millennium Pharmaceuticals, Inc.        Phase 1

14        BXQ-350        Bexion Pharmaceuticals, Inc.        Phase 1

15        exatecan mesylate        Daiichi Sankyo, Inc.        Phase 1

16        Fentanyl sublingual spray        INSYS Therapeutics Inc        Phase 3

17        5-Aminolevuline Acid        DUSA Pharmaceuticals, Inc.        Phase 2

18        CLR 131        Cellectar Biosciences, Inc.        Phase 1

19        Pomalidomide        Celgene        Phase 2

20        tozuleristide        Blaze Bioscience Inc.        Phase 2

21        Photofrin        Pinnacle Biologics Inc.        Phase 1

22        carmustine in ethanol        Direct Therapeutics        Phase 2

23        Lapatinib        GlaxoSmithKline        Phase 2

24        temozolomide        Jazz Pharmaceuticals        Phase 1

25        VEGF inhibitor PTC299        PTC Therapeutics        Phase 1

26        carboplatin        Amgen        Phase 1"
 

Chordoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Chordoma

"Chordoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

 

A chordoma is a rare type of cancerous tumor that can occur anywhere along the spine, from the base of the skull to the tailbone. Chordomas grow slowly, gradually extending into the bone and soft tissue around them. Changes in the TBXT gene have been associated with chordoma. The TBXT gene provides instructions for making a protein called brachyury.

 

According to Thelansis, worldwide one in one million people are diagnosed with chordoma per year.

 

Competitive landscape of Chordoma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

 

KOLs insights of Chordoma across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

 

Chordoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Chordoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No     Asset     Company           Stage

1            TAEK-VAC-HerBy             Bavarian Nordic Phase 2

2            GI-6301 NantCell, Inc.     Phase 2

3            FAZ053 Novartis Pharmaceuticals            Phase 1

4            Nivolumab         Bristol-Myers Squibb      Phase 2

5            Pemetrexed       Eli Lilly and Company     Phase 1

6            Afatinib Boehringer Ingelheim    Phase 2

7            BCA101 Bicara Therapeutics        Phase 1"

Neonatal Seizures – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Neonatal Seizure

Neonatal Seizure – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

The most common identifiable causes are hypoxic-ischaemic encephalopathy-HIE, cerebral infarction, cerebral trauma, central nervous system infection, metabolic abnormalities including hypoglycaemia, narcotic drug withdrawal, etc.

Clinical classification of neonatal seizures: Subtle, Clonic, Myoclonic and Tonic

Newborn babies have a central nervous system that is vulnerable to epileptogenic activity, and as a result they have a relatively high incidence of seizures (12 per 1,000 term infants).

Competitive landscape of Neonatal Seizure includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Neonatal Seizure across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Neonatal Seizure Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Neonatal Seizures – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No        Asset        Company        Stage

1        Lacosamide        UCB Biopharma SRL        Phase 3

2        Phenobarbital Sodium Injection        NEMA Research, Inc.        Phase 3"

Proteus Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Proteus Syndrome

"Proteus Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Proteus syndrome is a rare condition characterized by overgrowth of the bones, skin, and other tissues. Organs and tissues affected by the disease grow out of proportion to the rest of the body. Proteus syndrome results from a mutation in the AKT1 gene. The AKT1 gene helps regulate cell growth and division (proliferation) and cell death.Literature suggests that mutations in a gene called PTEN have been associated with Proteus syndrome.

According to Thelansis Proteus syndrome is a rare condition with an incidence of less than 1 in 1 million people worldwide.

Competitive landscape of Proteus Syndrome includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Proteus Syndrome across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Proteus Syndrome Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Proteus Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No     Asset     Company           Stage

1            Miransertib       ArQule, Inc.        Phase 2"